Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

Meihua Wang, Cong Chen, Thomas Jemielita, James Anderson, Xiaoyun Li, Chen Hu, S. Peter Kang, Nageatte Ibrahim, Scot Ebbinghaus

Research output: Contribution to journalArticle

Abstract

Background: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. Methods: Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs. Results: The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10% tumor reduction appeared to be reasonable for predicting survival. Conclusions: An approximate 10% tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation. Trial registration: Clinical trials gov, NCT01295827, Registered February 15, 2011; NCT01704287, Registered October 11, 2012; NCT01866319, Registered May 31, 2013.

Original languageEnglish (US)
Article number39
JournalJournal for immunotherapy of cancer
Volume7
Issue number1
DOIs
StatePublished - Feb 8 2019

Fingerprint

Immunotherapy
Melanoma
Neoplasms
Decision Making
Medical Oncology
Clinical Trials
Weights and Measures
Response Evaluation Criteria in Solid Tumors

Keywords

  • Cut-off values
  • Early efficacy metrics
  • Early tumor size changes
  • Immunotherapy trials
  • RECIST

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma? / Wang, Meihua; Chen, Cong; Jemielita, Thomas; Anderson, James; Li, Xiaoyun; Hu, Chen; Kang, S. Peter; Ibrahim, Nageatte; Ebbinghaus, Scot.

In: Journal for immunotherapy of cancer, Vol. 7, No. 1, 39, 08.02.2019.

Research output: Contribution to journalArticle

Wang, Meihua ; Chen, Cong ; Jemielita, Thomas ; Anderson, James ; Li, Xiaoyun ; Hu, Chen ; Kang, S. Peter ; Ibrahim, Nageatte ; Ebbinghaus, Scot. / Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?. In: Journal for immunotherapy of cancer. 2019 ; Vol. 7, No. 1.
@article{d7f9ebbb397547f3b167cb3dae2f64a6,
title = "Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?",
abstract = "Background: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. Methods: Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs. Results: The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10{\%} tumor reduction appeared to be reasonable for predicting survival. Conclusions: An approximate 10{\%} tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation. Trial registration: Clinical trials gov, NCT01295827, Registered February 15, 2011; NCT01704287, Registered October 11, 2012; NCT01866319, Registered May 31, 2013.",
keywords = "Cut-off values, Early efficacy metrics, Early tumor size changes, Immunotherapy trials, RECIST",
author = "Meihua Wang and Cong Chen and Thomas Jemielita and James Anderson and Xiaoyun Li and Chen Hu and Kang, {S. Peter} and Nageatte Ibrahim and Scot Ebbinghaus",
year = "2019",
month = "2",
day = "8",
doi = "10.1186/s40425-019-0513-4",
language = "English (US)",
volume = "7",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

AU - Wang, Meihua

AU - Chen, Cong

AU - Jemielita, Thomas

AU - Anderson, James

AU - Li, Xiaoyun

AU - Hu, Chen

AU - Kang, S. Peter

AU - Ibrahim, Nageatte

AU - Ebbinghaus, Scot

PY - 2019/2/8

Y1 - 2019/2/8

N2 - Background: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. Methods: Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs. Results: The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10% tumor reduction appeared to be reasonable for predicting survival. Conclusions: An approximate 10% tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation. Trial registration: Clinical trials gov, NCT01295827, Registered February 15, 2011; NCT01704287, Registered October 11, 2012; NCT01866319, Registered May 31, 2013.

AB - Background: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials. Methods: Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs. Results: The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10% tumor reduction appeared to be reasonable for predicting survival. Conclusions: An approximate 10% tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation. Trial registration: Clinical trials gov, NCT01295827, Registered February 15, 2011; NCT01704287, Registered October 11, 2012; NCT01866319, Registered May 31, 2013.

KW - Cut-off values

KW - Early efficacy metrics

KW - Early tumor size changes

KW - Immunotherapy trials

KW - RECIST

UR - http://www.scopus.com/inward/record.url?scp=85061262296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061262296&partnerID=8YFLogxK

U2 - 10.1186/s40425-019-0513-4

DO - 10.1186/s40425-019-0513-4

M3 - Article

C2 - 30736858

AN - SCOPUS:85061262296

VL - 7

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 39

ER -